title: [The application of the CO2 laser combined with pingyangmycin in the management of pharyngeal and laryngeal hemangioma].
abstract: OBJECTIVE
  To review our experience with the use of the CO2 laser combined with pingyangmycin in the treatment of pharyngeal and laryngeal hemangioma.
  
  
  METHODS
  A retrospective review of 18 patients with pharyngeal and laryngeal hemangioma treated with CO2 laser combined with pingyangmycin was carried out in our hospital: patients medical charts were evaluated for factors such as age, sex, location of hemangioma, number of laser procedures performed, and postoperative results, including short and long term complications.
  
  
  RESULTS
  All the 18 patients were underwent operation without any complications such as pharyngeal and laryngeal hemorrhage, infection of incisional wound,laryngeal edema, etc. Data of follow-up for 7 months to 5 years, showed that excellent local control was achieved in all cases with the exception of one case of recurrence. The one case recurred 4 months after operation and treated with CO2 laser again.
  
  
  CONCLUSIONS
  With careful selection of patients, the CO2 laser combined with pingyangmycin pingyangmycin is a safe and effective treatment for pharyngeal and laryngeal hemangioma with the following advantages: precise location for treating, less bleeding, clear operating field, simple management, low risk of infection, less post-operation reaction, protection of laryngeal and pharyngeal structures and avoidance of tracheostomy.
authors.affiliation: Department of Otolaryngology Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, China. entdoctor.wy@gmail.com
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Renyue
authors.initials: R
authors.lastname: Deng
authors.forename: Jining
authors.initials: J
authors.lastname: Qu
authors.forename: Zezhang
authors.initials: Z
authors.lastname: Tao
authors.forename: Qingquan
authors.initials: Q
authors.lastname: Hua
mesh_terms: D000328:Adult; D001761:Bleomycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006391:Hemangioma / Q000628:therapy*; D006801:Humans; D007013:Hypopharynx; D007830:Larynx; D054020:Lasers, Gas / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001761:Bleomycin; C025703:bleomycetin